Refractory Hypertension Clinical Trial
Official title:
Mechanisms of Refractory Hypertension (Reserpine)
The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.
Patients with refractory hypertension, defined as uncontrolled office blood pressure despite use of 5 or more antihypertensive agents, including a thiazide diuretic and spironolactone. After withdrawal from other centrally-acting agents if needed, enrolled patients will be randomized to open-label reserpine 0.1 mg daily for 4 weeks. Twenty-four hour ambulatory blood pressure monitoring will be done at baseline, after the initial 4-week treatment period. All other antihypertensive medications will remain unchanged during the 4-week treatment period. The primary endpoint will be change in 24-hr ambulatory systolic blood pressure. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04213963 -
Prospective Study on Primary Aldosteronism in Resistant Hypertension
|
||
Completed |
NCT00812695 -
Effects of Continuous Positive Airway Pressure (CPAP) in Patients With Resistant Hypertension and Obstructive Sleep Apnea (OSA)
|
Phase 3 | |
Terminated |
NCT00899977 -
TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension
|
Phase 1/Phase 2 | |
Completed |
NCT00746902 -
Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome
|
Phase 3 | |
Completed |
NCT01656096 -
Renal Sympathetic Denervation in Mild Refractory Hypertension
|
Phase 4 |